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Results. Ejection fraction was 29+7% (mean&D), the pulmonary capillary wedge pres- 
sure was l&7 mmHg, left ventricular end-diastolic pressure was 22*6 mmHg and mean 
pulmonary artery pressure (mPAP) was 26~6 mmHg. Plasma ET-l levels were similar in 
pulmonary artery (0.931*0.71 fmol/ml) and aorta (0.906*0.6 fmol/ml. p=O.769) and did 
not correlate with mPAP (r-0.139, p&521). Single pass pulmonary ET-l extraction was 
reduced compared with histoncal controls (31*15% vs 47*2%, p<O.OOl), as was plaSma 
clearance of ET-1 (912+610 mllmin YS 1424+77 mllmin, p=O.Ol). Lung clearance 
inversely correlated with mPAP (r=-0.490. p=O.O14). 
Conclusions. Pulmonary ET-l clearance is reduced in relation with the severity of pulmo- 
nary hypertension (PHT) in patients with CHF. While it does not seem to contribute to the 
increase in plasma ET-l levels, this evidence for reduction in endothelial ETB receptor 
activity may contribute to the development of PHT. 
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1062-59 What Is in the Differential Diagnosis of a B-Type 
Natriuretic Peptide Level of 1,000 pg/ml? 
1061-82 Evaluation of Platelets in Heart Failure: Is Platelet 
Activity Related to Etiology, Functional Class, or 
Clinical Outcomes? 
Peter A. McCullouah, Richard M. Nowak. James McCord, Torbjorn Omland, Catherine 
W. Knudsen. Philipoe Due. Judd E. Hollander. Philippe Gabriel Step. Marie-Claude 
Aumont, Arne Wes;heim. Alan B. Storrow, William f: Abraham, S&ant Lamba, Alan H. 
Wu. Alan S. Maisel. BNP Multinational Studv Investiaators. William Beaumont HosDital. 
Paul A. Gurbel, Wendy A. Gatt~s. Sergey F. Fuzaylov, Laura Gaulden, Vie Hasselblad, 
Victor L. Serebruanv. ChristoDher M. O’Connor. Sinai Center for Thrombosis Research, 
Baltimore, MD, Duke University Medical Center, Durham, NC 
Objectives: We sought to determine whether platelet activity in patients with heart failure 
(HF) is related to an ischemic versus non-ischemic etiology, clinical disease severity or 
adverse clinical outcomes. Background: Platelets activity may affect outcome in patients 
with HF. A prospective evaluation of the relation of baseline platelet function to HF etiol- 
ogy, NYHA class, and clinical outcomes has not been previously reported. Methods: 
Ninety-sir consecutive ambulatory hearl failure outpatients with an EFc .40 and NYHA 
Class II-IV symptoms who presented to the Duke Heart Failure Clinic and fourteen 
healthy controls formed the study groups. Baseline characteristics were determined and 
blood was analyzed for thromboxane (TX) 82, 6-ksto PGFI, platslst contractile force, 
ADPlcollagen shear-induced closure time, whole blood aggregation (WBA) and CD 41, 
CD31, CD62p and CD51/CD61 by flow cytometry. Survival status and hospitalizations 
were determined in the heart failure patient cohort. Results: The median age was 65 
years (22% female, 64% Caucasian). An ischemic etiology was present in 61%. The pop- 
ulation has mild-moderate HF: NYHA class I (l%), II (41%), Ill (46%), and IV (12.5%) and 
severe ventricular dysfunction (median EF = .20). There were 39 clinical events ( 7 
deaths, 3 cardiac transplants, 29 other first hospitalizations) in 305 median days follow- 
up. Platelet activity, indicated by WBA with 5pmol ADP (p=.O4) and TX 82 (p=.Ol), was 
higher in HF patients. WBA was greater than 90” percentile in 22% of HF patients vs 7% 
of controls. Markers of platelet function did not differ between the ischemic and non- 
ischemic groups and was not affected by antecedent aspirin. There was no relation of 
NYHA class or the occurrence of events to platelet activity. Conclusion: Platelet activity 
is heightened in 22% of outpatients with stable heart failure symptoms and is not affected 
by antecedent aspirin therapy. The degree of platelet activation is similar in ischemic and 
non-ischemic HF and is not related to clinical disease severity. Current methods to 
assess platelet activation do not appear to predict outcome. 
1061-83 Uric Acid and Survival In Chronic Heart Failure: 
Validation and Application In Metabolic, Functional, and 
Hemodynamic Staging 
Stefan D. Anker, Wolfram Doshner. Mathias Rauchhaus, Christoph Knosalla, Roland 
Hetzer, Andrew J. Coats, NHLI London, London, United Kingdom, Charit& Medical 
School, Berlin, Gsrmany 
Background: Serum uric acid (UA) could be a valid prognostic marker and useful for 
metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF). 
Methods: We performed a series of 3 studies. For the initial derivation study, 112 CHF 
patients (age 59*12 y, peak oxygen consumption [VO,] 17f7 mL/kg/min) were recruited. 
We validated the prognostic value of UA in a second, independent study (n=l82). In a 
third study, we investigated the relationship between MFH score and the decission to list 
patients for heart transplantation (rx120). 
Results: In the derivation study (12.month mortality: 24%) the best mortality predicting 
UA cut-off (at 12 months) was 565 pmol/L (independently of age, peak VQ, LVEF, 
diuretic dose, sodium, creatinine, and urea: pcO.0001). In the validation study (12-month 
mortality: 15%). UA _2565ymol/L predicted mortality (hazard ratio 7.14, p<O.OOOl). 
In 16 patients (from both studies) with UA &65 pmol/L, LVEF X25%, and peak VQ >14 
mUkglmin(i.e. with MFH score 3), 12-month survival was lowest (31%), compared to 
patients with 2 (64%). 1 (77%). or no risk factor (98% , p<O.OOOl). Considering all 294 
CHF patients, we found a graded relationship between serum UA and mortality in CHF 
(pcO.0001). Patients with UA in the normal range (a00 ~ol/L) had the best survival (at 
12.months: 93%). compared to patients with UA between 401 and 600 vol/L (87%, RR 
1.76), patients with UA between 601 and 800 pmol/L (54%, RR 6.27), and patients with 
UA >800 wol/L (17%. RR 18.53). 
In an independent study, 51% of patients with MFH score 2 and 89% of patients with 
MFH score 3 were listed for transplantation. The positive predictive value of not being 
listed for heart transplantation with an MFH score O/l was 100%. 
Conclusions: High serum UA levels are a strong and independent marker of impaired 
prognosis in patients with moderate to severe CHF. The relationship between serum UA 
and survival in CHF is graded. MFH staging of CHF patients is feasible 
Royal Oak, MI, University of California, San Diego School of Medicine, Veterans Affairs 
Medical Center, San Diego, CA 
Introduction Recent, approved indications for blood B-type natriuretic peptide (BNP) for 
the diagnosis of congestive heart failure (CHF) and as a prognostic indicator in patients 
with acute coronary syndromes raise questions on how to interpret very high BNP val- 
ues. 
Methods The BNP Multinational Study was a seven-center prospective study of 1586 
patients presenting with acute dyspnea who had blinded BNP levels measured. The ref- 
erence standard for CHF was adjudicated by two independent cardiologists, also blinded 
to BNP results. 
Results A total of 264 subjects (mean age 70.4 years, 57.2% male) had BNP values on 
arrival to the ED of> 1000 pg/ml. Subjects had the following characteristics: prior history 
of CHF 62.1%, history of coronary heart disease 48.5%, hypertension 65.5%, and lung 
disease in 30.3%; physical exam: rales 69.7%, 53 18.9%, elevated jugular venous pres- 
sure 44.3%, hepatic congestion 24.6%, and peripheral edema 66.3%. Abnormal chest x- 
rays wers present in 90.5%. The final diagnoses are shown in the pie chart. Of those with 
pulmonary disease, all subjects had at least one sign of volume overload on physical 
exam. Other diseases in the differential included atrial fibrillation, acute cardiac ishemis.. 
and chronic renal failure. 
Conclusion A BNP level -> 1000 pglml indicates the presence of CHF in 93.2% of 
cases. In 6.8% of cases without CHF, other serious conditions are present suggesting 
cardiac pressure and or volume overload. 
L 
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1062-60 The Prognostic Value of Inflammatory and 
Neurohumoral Activation in Patients With Chagas’ 
Heart Dlsease 
Victor S. Issa, Amilcar 0. Mocelin, Fernando Bacal, Guilherme V. Guimaraes, Edecio 
Cunha. Giovanni V. Belloni. Jose F. Ramires, Edimar A. Bocchi, Heart Institute (InCor)- 
University of Sao Paula Medical School, Sao Paul& Brazil 
Background. Inflammatory mediators are of paramount importance in heart failure. 
Despite experimental evidence that cytokines play a central role in Chagas’ disease, data 
in humans is scarce. We studied the pattern of inflammatory and neurohumoral response 
in patients with Chagas’ disease as compared to patients with idiopathic dilated cardi- 
omyopathy (IDC). 
Methods. We studied 35 patients with IDC (IDC group) and 28 patients with Chagas’ 
heart disease (CHAGAS group); we measured and compared plasma tumor necrosis 
factor alfa (TNF-a), soluble TNF-a receptor type l(sTNF-RI), soluble Fas (SF@, inter- 
leukin 6 (IL-6), and brain natriuretic peptide (BNP) concentrations in both groups; the 
association between the substances measured and clinical events (heart transplantation 
or death) was ascertained. Patients were stratified according to functional class and peak 
oxygen consumption (VOPmax). 
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Results. Plasma TNF-a level was higher in IDC (mean 4.82; 95% confidence intewal 
3.82607 pg/ml) and CHAGAS (8.28 pg/ml; 4.98.7.94pg/ml) as compared to controls 
(1.30pg/ml; 0.93-1.63 pg/ml)(pcO.OOl). Plasma TNF-a level was higher in CHAGAS than 
in IDC after stratification for VOPmax (p=O.O49). Plasma sTNF-Rl level was higher in 
IDC only after stratification for functional class (p=O.O4). Plasma of IL-8 level were higher 
in IDC (3.18 pg/ml; 2.35-4.32 pgfml) and in CHAGAS (6.07pgIml; 4.42-8.36pg/ml) as 
compared to controls (0.84pgiml; 0.63-l .12pg/ml); plasma IL-6 concentration was higher 
in CHAGAS than in IDC after stratification for functional class (p=O.O05). Higher IL-8 lev- 
els were associated with worst clinical outcome (p=O.O3 for group I; p=O.O03 for group II); 
Plasma BNP concentrations were higher in IDC (350pglml) and in CHAGAS (444.8pgl 
ml) as compared to controls (20.3pg/ml)(p~0.001); higher BNP level was associated to 
death and heart transplantation. Plasma sFas level was similar among the groups. 
Conclusions. Systemic inflammatory and neurohumoral activation is present in patients 
with Chagas’ heart disease, differs from patients with IDC and is associated with heart 
failure severity and outcome. Thus, it should be considered in the follow-up of patients 
with Chagas’ heart disease. 
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1062-61 B-Type Natriuretic Peptide Predicts Cardiac Injury and 
Dysfunction After Subarachnoid Hemorrhage 
Povee P. Tung, Alexander Kopelnik, Nader M. Banki. Michael Lawton, Daryl Gress, 
Barbara Drew, Elyse Foster, William Young. William Parmley, Jonathan G. Zaroff. UCSF 
Medical Center, San Francisco, CA 
Background: An elevated B-type natriuretic peptlde (BNP) level is a poor prognostic 
marker in heart failure and myocardial infarction. However, its role in neurocardiogenic 
injury after subarachnoid hemorrhage @AH) is unknown. In this study, we sought to 
determine the relationship between BNP and cardiac outcomes after SAH. Methods’ We 
conducted a prospective study in 57 patients admitted for SAH. On day 1.3. and 6 after 
enrollment, we collected clinical data (serum troponin I, two-dimensional echocardiogram 
and chest radiograph) on our subjects. Serum BNP and C-reactive protein levels were 
measured as soon as possible. 
Results: The mean BNP level was 3222 518 pg/ml (range 0.8. 3330 pg/ml). Wilcoxon 
rank-sum tests showed a significant relationship between elevated BNP levels and car- 
diac endpoints, defined as a high regional wall motion score, impaired diastolic function 
(impaired relaxation, pseudonormalization, restrictive physiology), radiographic evidence 
of pulmonary edema, and an elevated troponin I level (see table). In contrast, CRP level, 
a marker of inflammation, was not associated with any short-term cardiac outcome after 
SAH. 
Conclusions: Elevated BNP, but not CRP, is associated with cardiac injury and dysfunc- 
tion after SAH. These findings are consistent with the hypothesis that neurocardiogenic 
injury after SAH is related to neurohumoral activation rather than systemic inflammation. 
BNP may be a useful marker in identifying SAH patients at high risk of cardiac complica- 
tions 
BNP IS related to cardmc endpoints afier SAH 
Mean + SD 
(pglmt) 
RWMS 267 533 “S -+ 
(l.ovs>l.o) 488 f 441 
Diastolic function 128_+174vs 
(normal vs abnormal) 383 + 570 
Pulmonary edema on chest radiograph 195 -+ 248 vs 
(no “S yes) 1096 + 965 
Troponin I 240 _+508 vs 
(cl .o YS >l .o UglL) 682 -+ 429 
P N (%) with cardiac 
endpoints 
0.0 14 (25) 
32 
0.0 44 (77) 
37 
0.0 8(14) 
01 
0.0 11 (19) 
04 
1062-84 Phenotypic and Genotypic Heterogeneity in Cardiac 
Amyloidosis 
Enrica Perugini, Claudia Rapezzi, Fabrizio S&i, Michela Sank Giovanni Bracchetti, 
Carlo Magelli, Ornella Leone, Angelo Branzi. Institute of Cardiology, Bologna, Italy, 
Bellaria Hospital, Bologna, Italy 
Background. Most of the current knowledge on cardiac amyloidosis comes from the AL 
type (#I which precursor plasma protein is an immunoglobulln light chain) while the char- 
acteristics of myccardial involvement and the possible genotype-phenotype correlations 
in AlTR (caused by mutant transthyretin produced by the liver) remain to be defined. 
MethodsWe compared echocardiographic and clinical findings of three groups of 
patients with established amyloidotic myocardial involvement: 60 of AL type, 10 with 
ATTR Met30 mutation (in which methionine replaces valine at position 30). 16 with non- 
Met30 ATTR mutations. We also considered ATTR pts as a single group. 
Results 
47i2.8 
162~12 
0 
IVS = Interventricular Septal thickness; LPW = Left Posterior Wall thickness: LVEDD = 
Left Ventricular End-Diastolic Internal Dimension: LV = Left Ventricular; LA = Left Atrial 
end-systolic diameter; FS = Fractional Shoriening; 
Conclusions. Myocardial involvement is more severe in AL than in ATTR. This explains 
why AL patients develop more frequently diastolic and systolic dysfunction and clinical 
signs of heart failure. A genotype - phenotype correlation does exist within AlTR amyloi- 
dosis. A wide spectrum of morphologic and functional involvement is detectable in car- 
diac amyloidosis. This impairment is maximal in AL, intermediate in non-Met30 ATTR 
and minimal in Met30 ATTR. 
1062-85 Does Pericardiectomy Improve Outcome of Patients 
With Mixed Constriction and Restriction? 
Hirotsuau Yamada, Jeanne K. Drinko, Annitta J, Morehead, Leonardo Rodriguez, Mario 
J. Garcia, James D. Thomas, Allan L. Klein, The Cleveland Clinic Foundation, Cleveland, 
OH 
Background: Pericardiectomy can relive symptom in most patients with constrictive 
pericarditis. However, a significant subgroup of these patients has also restrictive myo- 
cardial involvement. The outcome of patients with this mixed disease has not been well 
described. Methods: Study subjects consisted of 38 patients (57 + 14 yrs. 8 female, 30 
male) who were diagnosed as having mixed physiology based on clinical history, tran- 
sthoracic and/or transesophageal echocardiography, MRI, cardiac catheterization. 
endomyocardial biopsy and/or surgical findings. Major etiology of the patients included 
coronary bypass surgery (CABG) after radiation (11), radiation therapy alone (8), CABG 
without radiation (9), idiopathic (4), heart transplantation (3). Seventeen patients treated 
with pericardiectomy (58 * 15 yrs) and 21 patients treated medically (57 * 14 yrs) were 
compared using Kaplan-Meier survival analysis. Results: There were no differences in 
age, left ventricular ejection fraction, prior radiation between both groups. Mean obsewa- 
tlon time was 4.0 f 3.8 years and maximum observation period was 13.4 years. Five 
years mortality was 51% in the pericardiectomy group and 58% in the medical therapy 
group and the survival was not significantly different between both groups (p = 0.739, fig- 
ure). Conclusions: Patients with mixed physiology of constriction and restriction have a 
high mortality rate. Pericardlectomy for these pattents may not improve their survival 
time. 
1062-86 Cardiac Function in Patients With Fukuyama-Type 
Congenital Muscular Dystrophy 
Toshio Nakanlshi, Masako Sakauchi, Hirofumi Tomimatsu. Kayoko Saitou. Makoto 
Nakazawa. Makiko Oosawa. Tokyo Women’s Medical University, Tokyo, Japan 
Backgroud: Fukuyama-type congenital muscular dystrophy (FCMD) is an autosomal 
recessive disorder characterised by generalised skeletal muscle weakness and hypoto- 
nia from early infancy and mental retardation. Mutation of fukutin gene on chromosome 
